Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussion reflects moderate enthusiasm and engagement, with posts highlighting its weekly injections, effects on insulin and glucagon, and potential to revolutionize diabetes and obesity treatments. The tone suggests cautious optimism, exemplified by phrases like 'new era' and 'promising', while some comments focus on mechanisms like gastric emptying and insulin secretion, indicating analytical interest.
Most discussions acknowledge the promising aspects of Tirzepatide and its dual-targeted approach, indicating general support.
The conversations show moderate interest, with participants discussing mechanisms and potential benefits but not expressing extreme enthusiasm or skepticism.
Some posts delve into specific physiological effects such as reductions in gastric emptying and glucagon secretion, reflecting a moderate level of discussion depth.
The overall influence appears balanced: the publication seems significant but not revolutionary in the immediate context, with some posts referencing new treatment possibilities.
#mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review” By: Vivek P. Chavda, et al.
RT @Molecules_MDPI: #mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obes…
RT @Molecules_MDPI: #mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obes…
RT @Molecules_MDPI: #mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obes…
抗肥満薬Tirzepatide "GLP-1受容体作動薬はα細胞を介して膵臓のグルカゴン分泌を減少させ、胃内容排出時間を短縮し、食欲と栄養素の摂取を減少させ、体重減少を引き起こす。" https://t.co/pfeGydXGv1
RT @Molecules_MDPI: #mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obes…
This video explains how Tirzepatide, known as Mounjaro, works by targeting GLP-1 and GIP receptors to control blood sugar and promote weight loss, highlighting its potential for treating diabetes and obesity.
Ozempic's days are numbered. A new diabetes medication approved in Brazil, Mounjaro, surpasses Ozempic in weight loss, but what are its side effects and precautions? Learn essential information about this innovative…
抗肥満薬Tirzepatide "GLP-1受容体作動薬はα細胞を介して膵臓のグルカゴン分泌を減少させ、胃内容排出時間を短縮し、食欲と栄養素の摂取を減少させ、体重減少を引き起こす。" https://t.co/pfeGydXGv1
@baxirahul Tirzepatide once a week injections reduces gastric emptying and decreases glucagon secretions and increase insulin secretions https://t.co/lfFv5wSCk0 https://t.co/63GlRM43tc
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review https://t.co/QWDZ39elzW
RT @Molecules_MDPI: #mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obes…
RT @Molecules_MDPI: #mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obes…
RT @Molecules_MDPI: #mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obes…
RT @Molecules_MDPI: #mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obes…
#mdpimolecules #NewPublication New Publication “Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review” By: Vivek P. Chavda, et al.